Appointment of experts to support the development of the lead applicant VMB-100, an RNA-based therapy for stress urinary incontinence
BASEL, Switzerland, February 24, 2022 /PRNewswire/ — Versameb AG (“Versameb”), specializing in the discovery and development of innovative RNA-based drugs, today announces the formation of an advisory board comprised of industry leaders from urology. These include the teacher Roger Dmochowski of Vanderbilt UniversityProfessor Margot Damaser from Cleveland Clinic Lerner College of Medicine and Assistant Professor Frédéric Birkhäuser from St. Anna and Hirslanden Clinic Lucerne.
Versameb is building a pipeline of promising first-class RNA therapies based on its next-generation RNA platform technology, VERSagile. The newly formed Board of Directors will advise on the clinical development of its lead candidate, VMB-100, for the treatment of stress urinary incontinence (SUI) which is currently undergoing development activities preclinical advances and is expected to enter clinical development in the second half of 2022.
Up to 50% of adult women experience SUI at some point in their lives without currently approved restorative drug treatment. Physical changes resulting from pregnancy, childbirth, and menopause are risk factors for the development of SUI. VMB-100 has first class potential and has generated promising preclinical data showing regeneration of muscle tissue and restoration of urinary sphincter function.
Klaas Zuideveld, CEO of Versameb, said: “The formation of an advisory board marks an important milestone for Versameb as we advance our lead candidate in stress urinary incontinence towards clinical development. We are delighted and honored to work with three global experts in the field whose individual expertise and in-depth knowledge will be particularly important as we move into clinical development.”
Roger Dmochowski is Professor of Urology, Chief Associate Surgeon for Vanderbilt University Medical Center, and world leader in the fields of urology and incontinence. He is a member of the Bone, Reproductive, and Urology Drugs Advisory Committee (BRUDAC) of the FDA and a co-author of the FDA guidelines for regenerative medicine in urology. He has led and participated in numerous clinical trials in incontinence and has received numerous awards, including the Lifetime Achievement Award from the Urodynamics Society for his achievements in the clinical treatment of incontinence. He is a director and past president of the American Board of Urology, a member of the American College of Surgeons, the American Urological Association and the International Continence Society. Dr. Dmochowski has published over 320 articles, 100 book chapters and 460 abstracts and over 260 presentations at various national and international meetings. He is editor-in-chief of Neurourology and Urodynamics and sits on the editorial board of several scientific journals.
Margot Damaser is a professor of biomedical engineering at the Cleveland Clinic Lerner College of Medicine in Case Western Reserve University and the staff of the Glickman Urological & Kidney Institute. During her distinguished career spanning over 25 years, she has studied urinary incontinence and pelvic floor disorders. His research focuses on the development and testing of new devices and regenerative approaches to improve the diagnosis and treatment of urinary incontinence, voiding disorders and pelvic floor disorders. She has expertise in animal models of stress urinary incontinence and pelvic floor disorders. She earned her doctorate in bioengineering from the University University of California, Berkeley and the San Francisco Bioengineering Program. She has published over 150 peer-reviewed scientific papers, served as a member of the National Institutes of Health (NIH) and other grant review study sections, and has served on several national advisory committees, including the Council Advisory of the National Institute of Diabetes and Digestive Diseases and Kidney Disorders (NIDDK) to the NIH. Dr. Damaser is a member of the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE), an honor reserved for the top 2% of biomedical engineers in the United States.
Frederic Birkhauser is co-lead urologist at the St. Anna and Hirslanden Clinic in Lucerne and consultant urologist at the Universities of Basel and Bern, Switzerland. He has been a co-investigator in numerous clinical trials in urology and uro-oncology and published on innovative surgical techniques and immuno-oncological approaches in kidney, bladder and prostate cancer. He is an examiner for the European Board of Urology and a member of the Swiss Medical Association, European Urological Association, Swiss Urological Society and American Urological Association.
Versameb AG is a private biotechnology company focused on the discovery and development of innovative RNA-based drugs for the modulation of protein expression, including the ability to influence multiple therapeutic targets simultaneously, in a controlled manner , with molecular construction and cell targeting. Situated at Basel and fully operational as of 2018, the company is led by an experienced science and management team with proven expertise in drug discovery and development, from lab to patient. Versameb’s proprietary technology platform, VERSagileoptimizes the application of functional RNA in different disease contexts – making RNA medicable in new therapeutic areas that others have not been able to solve.
The pipeline includes lead candidate programs in stress urinary incontinence (SUI) and solid tumors. Versameb is working on a first in-human/proof-of-concept clinical study while advancing its platform. You can find more information about Versameb on www.versameb.com as well as on LinkedIn.